Comparison of the Risk of Cancer Between Patients With Type 2 Diabetes Exposed to Dapagliflozin and Those Exposed to Other Antidiabetic TreatmentsFirst published 15/01/2016 Last updated 14/03/2024 EU PAS number: EUPAS12116StudyOngoingDownload as PDF